These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 36002369)

  • 41. The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.
    Chen H; Huang D; Lin G; Yang X; Zhuo M; Chi Y; Zhai X; Jia B; Wang J; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
    Cancer Med; 2022 Oct; 11(19):3581-3592. PubMed ID: 35394121
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
    Lee A
    Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting KRAS
    Torres-Jiménez J; Espinar JB; de Cabo HB; Berjaga MZ; Esteban-Villarrubia J; Fraile JZ; Paz-Ares L
    Drugs; 2024 May; 84(5):527-548. PubMed ID: 38625662
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-)mutations in non-small cell lung cancer with a special focus on KRAS G12C.
    Boeschen M; Kuhn CK; Wirtz H; Seyfarth HJ; Frille A; Lordick F; Hacker UT; Obeck U; Stiller M; Bläker H; von Laffert M
    Lung Cancer; 2023 Oct; 184():107361. PubMed ID: 37699269
    [TBL] [Abstract][Full Text] [Related]  

  • 45. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
    Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
    Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study.
    Garcia BNC; van Kempen LC; Kuijpers CCHJ; Schuuring E; Willems SM; van der Wekken AJ
    Lung Cancer; 2022 May; 167():1-7. PubMed ID: 35349855
    [TBL] [Abstract][Full Text] [Related]  

  • 47. KRAS G12C Mutant Non-Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer Registry.
    Isaksson J; Berglund A; Louie K; Willén L; Hamidian A; Edsjö A; Enlund F; Planck M; Vikström A; Johansson M; Hallqvist A; Wagenius G; Botling J
    Clin Lung Cancer; 2023 Sep; 24(6):507-518. PubMed ID: 37296038
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report.
    Boby JM; Mohd Ghazali NN; Mani A; George M
    J Med Case Rep; 2022 Nov; 16(1):420. PubMed ID: 36329437
    [TBL] [Abstract][Full Text] [Related]  

  • 49. KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.
    Park S; Kim JY; Lee SH; Suh B; Keam B; Kim TM; Kim DW; Heo DS
    Korean J Intern Med; 2017 May; 32(3):514-522. PubMed ID: 28407465
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current perspectives of KRAS in non-small cell lung cancer.
    Harris E; Thawani R
    Curr Probl Cancer; 2024 Aug; 51():101106. PubMed ID: 38879917
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
    Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced
    Thummalapalli R; Bernstein E; Herzberg B; Li BT; Iqbal A; Preeshagul I; Santini FC; Eng J; Ladanyi M; Yang SR; Shen R; Lito P; Riely GJ; Sabari JK; Arbour KC
    JCO Precis Oncol; 2023 Jun; 7():e2300030. PubMed ID: 37384866
    [TBL] [Abstract][Full Text] [Related]  

  • 53. First-in-Humans PET Imaging of
    Li X; Ye J; Wang J; Quan Z; Li G; Ma W; Zhang M; Yang W; Wang J; Ma T; Kang F; Wang J
    J Nucl Med; 2023 Dec; 64(12):1880-1888. PubMed ID: 37827842
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy.
    Noordhof AL; Damhuis RAM; Hendriks LEL; de Langen AJ; Timens W; Venmans BJW; van Geffen WH
    Lung Cancer; 2021 May; 155():163-169. PubMed ID: 33838467
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
    Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
    Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
    [TBL] [Abstract][Full Text] [Related]  

  • 56. KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing.
    Veluswamy R; Mack PC; Houldsworth J; Elkhouly E; Hirsch FR
    J Mol Diagn; 2021 May; 23(5):507-520. PubMed ID: 33618059
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acquired Resistance to KRAS
    Awad MM; Liu S; Rybkin II; Arbour KC; Dilly J; Zhu VW; Johnson ML; Heist RS; Patil T; Riely GJ; Jacobson JO; Yang X; Persky NS; Root DE; Lowder KE; Feng H; Zhang SS; Haigis KM; Hung YP; Sholl LM; Wolpin BM; Wiese J; Christiansen J; Lee J; Schrock AB; Lim LP; Garg K; Li M; Engstrom LD; Waters L; Lawson JD; Olson P; Lito P; Ou SI; Christensen JG; Jänne PA; Aguirre AJ
    N Engl J Med; 2021 Jun; 384(25):2382-2393. PubMed ID: 34161704
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS
    Hoshiyama H
    Nihon Yakurigaku Zasshi; 2023; 158(5):391-398. PubMed ID: 37673617
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆.
    Hames ML; Chen H; Iams W; Aston J; Lovly CM; Horn L
    Lung Cancer; 2016 Feb; 92():29-34. PubMed ID: 26775593
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.
    Svaton M; Fiala O; Pesek M; Bortlicek Z; Minarik M; Benesova L; Topolcan O
    Anticancer Res; 2016 Mar; 36(3):1077-82. PubMed ID: 26977001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.